EAS Congress: Lowering lipoprotein(a) for clinical benefit: How much?Low LDL cholesterol due to PCSK9 variants reduces mortality Real-world use of PCSK9 inhibitors First data from the Homozygous Familial Hypercholesterolaemia International Clinical Collaborators (HICC) Registry

About the PCSK9 Education and Research Forum

PCSK9 Education and Research Forum is the independent resource on PCSK9 science and its translation into critically important new treatments to lower low density lipoprotein cholesterol (LDL-C), which promise to transform the prognosis of millions of patients with hypercholesterolaemia (cholesterol disorders), accelerated atherosclerotic vascular heart disease and a high risk of premature cardiovascular (CV) death and disability.
Aims & Objectives Mission Statement Editorial Board Partnership & Outreach Forthcoming Meetings

Download NowUNIQUE FREE APPAdvances in lipid lowering - a clinical guide

News from 86th EAS Congress

More Late Breaker News: ORION-1 and EUROASPIRE V

How much lipoprotein(a) lowering is required for cardiovascular benefit?

FOURIER looks at impact of baseline lipoprotein(a)

News from ACC 2018

VIDEO: The Word from ACC 2018: ODYSSEY Outcomes

Highlights from ACC.2018: Poster presentations

Most viewed

Thank you for subscribing Videos Inclisiran marches on: ORION-4 cardiovascular outcomes study launches Editorial Board ODYSSEY Outcomes and FOURIER in context Trials Real-world use of PCSK9 inhibitors How best to optimise PCSK9 inhibition, considering findings from FOURIER and ODYSSEY Outcomes Low LDL cholesterol due to PCSK9 variants reduces mortality Will the PCSK9 inhibitor trials change guidelines and practice?

Most viewed

Thank you for subscribing

New Editorial : ‘New Approaches to PCSK9 inhibition’

Prof Derick Raal (University of Witwatersrand, Johannesburg, South Africa) discusses what’s in the pipeline for PCSK9 inhibition beyond the monoclonal antibodies
Read the report

Video: What's in the PCSK9 pipeline?
Watch the video

Hot Topics

Adverse effects of long-term statin therapy: New statement from the EAS Consensus Panel

Clinical trials have clearly proven the efficacy and short-term safety of statin treatment. But, with people taking these medications lifelong, are there any adverse effects to consider in the longer-term? This new statement weighs the evidence versus the perception of risk.

Read the report

Video: EAS Consensus Panel: Statins do not impair cognitive function
Watch the video

Report: Neurocognitive effects and PCSK9 inhibition
Read the report

From the Editors

PSCK9 inhibitor therapy- after the clinical trials, what can we learn to improve practice?

Anthony Wierzbicki

After the dust has settled from ACC 2018, Prof. Anthony S Wierzbicki, Guy’s and St Thomas’ Hospitals, London, UK discusses the latest data from the PCSK9 inhibitor trials that will aid risk stratification.

Read the article

FOURIER analysis: consistent benefit with evolocumab across the range of inflammatory risk

Read the report